Drug intelligence / Profile preview

WTX-002

Development stage: Preclinical
Lead developer: Wntrix
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

WTX-002 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Wntrix, a biotechnology company based in Houston, Texas. The therapeutic candidate is designed to target a proprietary, undisclosed novel membrane antigen that is highly enriched in specific tumor tissues, including liver and kidney cancers. By utilizing the targeting specificity of a monoclonal antibody to deliver a cytotoxic payload directly to malignant cells, WTX-002 aims to maximize anti-tumor efficacy while reducing systemic toxicity. It is currently undergoing preclinical optimization for potency, efficacy, and tolerability.

Beyond the preview

Go deeper on WTX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX-002.

Explore the full profile